A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML

The proportion of patients with acute myeloid leukemia (AML) cured is increased by administering high-dose cytarabine (HiDAC). It remains uncertain whether to administer HiDAC as induction or consolidation, and whether ≥1 cycle of HiDAC is required. Our retrospective study of 416 adult AML patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarer, Anthony P., Butler, Jason, Jackson, Kathryn, Beligaswatte, Ashanka, Martin, Louisa, Kennedy, Glen, Daniela, Zantomio, Lewis, Ian, Hiwase, Devendra, Wight, Joel, He, Simon, Grigg, Andrew, Morris, Kirk, Mollee, Peter, Marlton, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745967/
https://www.ncbi.nlm.nih.gov/pubmed/31723796
http://dx.doi.org/10.1097/HS9.0000000000000158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745967/
https://www.ncbi.nlm.nih.gov/pubmed/31723796
http://dx.doi.org/10.1097/HS9.0000000000000158

Ejemplares similares